摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-nitrobenzyl (5R)-6-[(acetyloxy)(5,8-dihydro-6H-imidazo[2,1-b][1,3]pyrano-[4,3-d][1,3]thiazol-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate | 623931-32-8

中文名称
——
中文别名
——
英文名称
4-nitrobenzyl (5R)-6-[(acetyloxy)(5,8-dihydro-6H-imidazo[2,1-b][1,3]pyrano-[4,3-d][1,3]thiazol-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
英文别名
4-nitrobenzyl(5R)-6-[(acetyloxy)(5,8-dihydro-6H-imidazo[2,1-b][1,3]pyrano[4,3-d][1,3]thiazol-2-yl)]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
4-nitrobenzyl (5R)-6-[(acetyloxy)(5,8-dihydro-6H-imidazo[2,1-b][1,3]pyrano-[4,3-d][1,3]thiazol-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate化学式
CAS
623931-32-8
化学式
C24H19BrN4O8S2
mdl
——
分子量
635.473
InChiKey
QIVPOHLXZOIVAT-HWDGFJGFSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.61
  • 重原子数:
    39.0
  • 可旋转键数:
    7.0
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    142.58
  • 氢给体数:
    0.0
  • 氢受体数:
    12.0

反应信息

  • 作为反应物:
    描述:
    4-nitrobenzyl (5R)-6-[(acetyloxy)(5,8-dihydro-6H-imidazo[2,1-b][1,3]pyrano-[4,3-d][1,3]thiazol-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylatesodium hydroxide 作用下, 以 四氢呋喃 、 phosphate buffer 、 乙腈 为溶剂, 反应 2.0h, 以30%的产率得到sodium;(5R,6Z)-6-(10-oxa-7-thia-2,5-diazatricyclo[6.4.0.02,6]dodeca-1(8),3,5-trien-4-ylmethylidene)-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
    参考文献:
    名称:
    5,5,6-Fused tricycles bearing imidazole and pyrazole 6-methylidene penems as broad-spectrum inhibitors of β-lactamases
    摘要:
    beta-Lactamases are serine- and metal-dependent hydrolases, produced by the bacteria as defense against beta-lactam antibiotics. Commercially available inhibitors such as clavulanic acid, sulbactam, and tazobactam, which are currently used in the hospital settings, have reduced activity against newly emerging beta-lactamases. Bacterial production of diverse beta-lactamases including class-A, class-C, and ESBLs has motivated several research groups to search for inhibitors with a broader spectrum of activity. Previously, several novel 6-methylidene penems bearing, [5, 5] [5, 6] and [5, 5, 5] heterocycles have been synthesized in our laboratory and were shown to be potent and broad-spectrum beta-lactamase inhibitors. As a continuation of our previous work and in order to extend the structure-activity relationships, in this paper, we describe herein the synthesis and in vitro, in vivo activities of several novel 5,5,6-fused tricyclic heterocycles attached to the 6-methylidene penem core. The compounds presented in the current paper are potent and broad-spectrum inhibitors of the TEM-1 and AmpC beta-lactamases. In combination with piperacillin, their in vitro activities showed enhanced susceptibility to class A- and C-resistant strains studied in various bacteria. Some of the newly synthesized compounds such as 12a-c were shown to have in vivo activity in the acute lethal infection model against TEM-1 producing organisms. The 5,5,6-fused heterocyclic ring cores such as 21, 25, and 35 reported here are hitherto unknown in the literature. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2007.11.006
  • 作为产物:
    描述:
    乙酸酐四氢呋喃乙腈 为溶剂, 反应 15.0h, 以400 mg的产率得到4-nitrobenzyl (5R)-6-[(acetyloxy)(5,8-dihydro-6H-imidazo[2,1-b][1,3]pyrano-[4,3-d][1,3]thiazol-2-yl)methyl]-6-bromo-7-oxo-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate
    参考文献:
    名称:
    5,5,6-Fused tricycles bearing imidazole and pyrazole 6-methylidene penems as broad-spectrum inhibitors of β-lactamases
    摘要:
    beta-Lactamases are serine- and metal-dependent hydrolases, produced by the bacteria as defense against beta-lactam antibiotics. Commercially available inhibitors such as clavulanic acid, sulbactam, and tazobactam, which are currently used in the hospital settings, have reduced activity against newly emerging beta-lactamases. Bacterial production of diverse beta-lactamases including class-A, class-C, and ESBLs has motivated several research groups to search for inhibitors with a broader spectrum of activity. Previously, several novel 6-methylidene penems bearing, [5, 5] [5, 6] and [5, 5, 5] heterocycles have been synthesized in our laboratory and were shown to be potent and broad-spectrum beta-lactamase inhibitors. As a continuation of our previous work and in order to extend the structure-activity relationships, in this paper, we describe herein the synthesis and in vitro, in vivo activities of several novel 5,5,6-fused tricyclic heterocycles attached to the 6-methylidene penem core. The compounds presented in the current paper are potent and broad-spectrum inhibitors of the TEM-1 and AmpC beta-lactamases. In combination with piperacillin, their in vitro activities showed enhanced susceptibility to class A- and C-resistant strains studied in various bacteria. Some of the newly synthesized compounds such as 12a-c were shown to have in vivo activity in the acute lethal infection model against TEM-1 producing organisms. The 5,5,6-fused heterocyclic ring cores such as 21, 25, and 35 reported here are hitherto unknown in the literature. (c) 2007 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2007.11.006
点击查看最新优质反应信息

文献信息

  • Tricyclic 6-alkylidene-penems as class-D beta-lactamases inhibitors
    申请人:Mansour Suhayl Tarek
    公开号:US20060276446A1
    公开(公告)日:2006-12-07
    This invention relates to certain tricyclic 6-alkylidene penems which act as a inhibitor of class-D enzymes. β-Lactamases hydrolyze β-lactam antibiotics, and as such serve as the primary cause of bacterial resistance. The compounds of the present invention when combined with β-lactam antibiotics will provide an effective treatment against life threatening bacterial infections. In accordance with the present invention there are provided compounds of formula I which are useful for treatment of bacterial infections having class-D enzymes associated therewith: wherein: One of A and B denotes hydrogen and the other an optionally substituted fused tricyclic heteroaryl group; and X is S or O.
    这项发明涉及某些三环6-烷基亚胺青霉素,其作为类D酶的抑制剂。β-内酰胺酶解β-内酰胺类抗生素,因此是细菌抗药性的主要原因。本发明的化合物与β-内酰胺类抗生素结合时,将提供一种有效治疗危及生命的细菌感染的方法。根据本发明,提供了以下公式I的化合物,其用于治疗与类D酶相关的细菌感染:其中:A和B中的一个表示氢,另一个表示可选择取代的融合三环杂芳基团;X为S或O。
查看更多

同类化合物

(6R,7R)-7-苯基乙酰胺基-3-[(Z)-2-(4-甲基噻唑-5-基)乙烯基]-3-头孢唑啉-4-羧酸二苯甲基酯 顺式-4-(2,2-二甲氧基乙基)-3-邻苯二甲酰-2-氮杂环丁酮 顺式-3-氨基-1-(2,4-二甲氧基苄基)-4-甲氧羰基-2-氮杂环丁酮 顺式-1-(对甲苯基)-3-苄氧基-4-(对茴香基)-氮杂环丁烷-2-酮 顺式-1,4-二苯基-3-(甲基苯基氨基)-2-氮杂环丁酮 青霉酰聚赖氨酸 青霉素钾 青霉素钠 青霉素酶液体 青霉素杂质F氢化物 青霉素杂质C 青霉素亚砜酯(GESO) 青霉素V二苄乙二胺 青霉素G衍生物 青霉素G甲酯 青霉素G甲酯 青霉素G-D7 青霉素 V 钠 阿那白滞素 阿莫西林钠 阿莫西林三水合物 阿莫西林 阿立必利D5 阿度西林 铜(2+)酞菁-29,30-二负离子-2-(二甲氨基)乙醇(1:1:1) 钾(2S,5R,6R)-6-[[2-[(E)-3-氯丁-2-烯基]巯基乙酰基]氨基]-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸酯 钠6-[[3-(2-氯-6-氟苯基)-5-甲基1,2-恶唑-4-羰基]氨基]-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸盐水合物 钠(6S,7R)-3-(羟基甲基)-7-甲氧基-8-氧代-7-[(2-噻吩基乙酰基)氨基]-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸酯 钠(6R,7R)-7-[[(2Z)-2-(2-氨基-1,3-噻唑-4-基)-2-甲氧基亚氨基乙酰基]氨基]-8-氧代-3-[(2S)-四氢呋喃-2-基]-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸酯 钠(2S,5R,6R)-6-[(2-叠氮基-2-苯基乙酰基)氨基]-3,3-二甲基-7-氧代-4-硫杂-1-氮杂双环[3.2.0]庚烷-2-羧酸盐 酞氨西林 赖氨酸氯尼辛 萘夫西林钠 萘夫西林钠 萘夫西林杂质 苯磺酸,2-[(2-羟基-1-萘基)偶氮]-5-甲基-,盐(2:1)钡 苯甘孢霉素亚砜 苯氧乙基青霉素钾 苯并[b]噻吩-3-羧酸,2-[3-氯-2-(4-硝基苯基)-4-羰基-1-吖丁啶基]-4,5,6,7-四氢-,乙基酯 苯唑西林钠 苯唑西林杂质1 舒巴坦杂质19 舒他西林 脱乙酰基戊二酰 7-氨基头孢烷酸 脱乙酰基头孢噻肟 肟莫南 羰苄西林苯酯钠 美罗培南钠盐 美罗培南 美洛培南